Study guide

1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions

BCSCP Board Certified Sterile Compounding Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, USP Standards & CSP Categories

1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions

2 Chapter 2: Facilities, Engineering Controls & Cleaning

2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures

3 Chapter 3: Environmental Monitoring & Facility Certification

3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols

4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique

4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity

5 Chapter 5: Beyond-Use Dating, Storage & Container Rules

5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules

6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding

6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)

7 Chapter 7: Materials, Equipment & Compounding Workflow

7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs

8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility

8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics

9 Chapter 9: Therapeutics, Administration & Patient Monitoring

9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations

10 Chapter 10: Quality Management, Records & Personnel Competency

10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence

11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain

11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA

12 Chapter 12: Safety Management, Investigations, Recalls & Waste

12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management

1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions

Key Takeaways Explain This Topic AI

USP <797> (official November 1, 2023) calls this provision immediate-use CSPs; there is no 'urgent-use' category in the chapter.

An immediate-use CSP may involve no more than 3 different sterile products, and administration must begin within 4 hours after preparation starts.

Unless the preparer administers the dose or witnesses its administration, the label must show every active ingredient and amount, the preparer's name or initials, and the 4-hour window.

Unused starting components from a single-dose container must be discarded after the preparation is complete; a single-dose container is never used for more than one patient under this provision.

The 2008 limits of 1 hour, 2 entries per container and 'emergency only' use are gone. Immediate-use CSPs may even be batched, if every condition is met.

Last updated: September 2026

1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions

Important

The chapter term is immediate-use CSP . Exam items may test whether you know the current conditions or the retired 2008 ones, such as the 1-hour limit and the 2-entry limit. Learn the current list exactly.

Why the provision exists

Some sterile doses must be mixed where and when the patient needs them, for example in a code, in the operating room, or in the emergency department. Taking every such dose to a cleanroom would delay care. USP <797> Section 1.3 therefore says that compounding for direct and immediate administration is not subject to the Category 1, 2 or 3 requirements, provided that all of the conditions below are met. If any condition is missed, the preparation is an ordinary CSP and must meet the category rules, including an ISO Class 5 PEC.

The seven conditions (USP <797> Section 1.3)

# Condition What it means in practice

1 Aseptic techniques, processes and procedures are followed, and written SOPs are in place SOPs must minimize contact with nonsterile surfaces, particulate or biological-fluid contamination, and mix-ups

2 Personnel are trained and have shown competency in aseptic processes for their tasks The facility's SOPs set how competency is assessed; USP sets no frequency and does not require media fills

3 The preparation follows evidence-based compatibility information Approved labeling, stability and compatibility studies

4 Not more than 3 different sterile products Several containers of the same product count as one product

5 Unused starting components from a single-dose container are discarded when the preparation is complete A single-dose container must not be used for more than one patient

6 Administration begins within 4 hours after preparation starts If it has not begun by then, the CSP is promptly and safely discarded

7 Labeling , unless the preparer administers the dose or witnesses its administration Names and amounts of all active ingredients, the preparer's name or initials, and the 4-hour period

Counting "3 different sterile products"

USP's FAQ gives worked examples. Two vials of the same drug reconstituted with two vials of Sterile Water for Injection and added to one bag of 0.9% sodium chloride uses three different products (the drug, the water and the saline). Four vials of one drug added to one bag uses only two different products. Count product identities , not containers.

Compliant: norepinephrine vials + one 250 mL bag of dextrose 5% (2 different products).

Not compliant: a bag of sterile water + sodium chloride concentrate + potassium chloride + calcium gluconate (4 different products). This must be prepared as a Category 1 or higher CSP in an ISO Class 5 PEC.

The 4-hour clock

Loading diagram...

The clock starts at the start of preparation , not when mixing ends or when the dose reaches the bedside.

Only the start of administration must fall inside the 4 hours. An infusion that begins at hour 3 may run for its ordered duration.

The 4-hour window is USP's microbiological limit. It rests on the roughly 4-to-6-hour lag phase before introduced bacteria start to multiply. It does not override a shorter chemical stability limit in the product labeling.

A facility may keep a stricter 1-hour policy. USP's FAQ says that choice is acceptable.

Labeling

A label is required unless the person who prepared the CSP directly administers it , or witnesses its administration. When required, the label shows:

  • The names and amounts of all active ingredients
  • The name or initials of the person who prepared it
  • The 4-hour time period within which administration must begin (for example, "Prepared 14:15 - begin by 18:15")

Patient identifiers are normally added under institutional policy, but they are not one of the three USP <797> immediate-use label elements.

What changed from the 2008 chapter

  • Feature 2008 immediate-use Current immediate-use (2022 revision, official 2023)
  • Administration deadline Begin within 1 hour of preparation start Begin within 4 hours of preparation start

Product limit Not more than 3 commercially manufactured sterile, nonhazardous products Not more than 3 different sterile products

Container entries Not more than 2 entries into any one container No entry limit in the chapter

Scope Emergencies or immediate administration where cleanroom preparation would harm the patient Any CSP for direct and immediate administration that meets all conditions

Batching Not contemplated Allowed for one or more patients if every condition is met; a compounding record is then required

Because the chapter now allows immediate-use doses to be batched , a CSP made for more than one patient needs a compounding record (USP <797> Section 11.2).

Hazardous drugs

Section 1.3 of USP <797> does not itself mention hazardous drugs. USP <800> still applies, though. It requires sterile hazardous drugs that need manipulation, including every NIOSH Table 1 antineoplastic and any hazardous drug active pharmaceutical ingredient (API), to be compounded in an externally vented C-PEC inside a C-SEC . Only a documented assessment of risk can allow alternative containment for eligible dosage forms. So reconstituting methotrexate or cyclophosphamide at a nursing station as an "immediate-use" dose violates USP <800>, even though the USP <797> exemption is silent on hazardous drugs.

Common traps

Using the old term or old limits. There is no 2-entry rule and no 1-hour rule in the current chapter.

Timing the clock from arrival on the unit. The clock runs from the start of preparation.

Reusing a single-dose vial for the next patient. Leftover single-dose components are discarded when the preparation is complete.

Assuming media-fill tests are required. For staff who make only immediate-use CSPs, the facility's SOPs define how competency is evaluated.

Treating the exemption as permission for poor technique. Aseptic technique, SOPs and evidence-based compatibility are all still required.